ReviewInternational journal of molecular sciences2016
Severe Cutaneous Adverse Reactions: The Pharmacogenomics from Research to Clinical Implementation.
Review in International journal of molecular sciences, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 1 synthesis or guideline pooled it, 43 citations in OpenAlex.
- Association between HLA-B*5901 and methazolamide-induced Stevens-Johnson syndrome/toxic epidermal necrolysis: a systematic review and meta-analysis.The pharmacogenomics journal · 2019Pooled it
- Structural evolution of polymorphic class I HLA alleles, designating HLA-C with uncertain assemblies.Computational and structural biotechnology journal · 2026Article
- Severe cutaneous adverse reactions.Nature reviews. Disease primers · 2024Review
- Severe Cutaneous Adverse Drug Reactions at a Tertiary Care Center in Saudi Arabia.Dermatology research and practice · 2023Article
- Pharmacogenomics in clinical trials: an overview.Frontiers in pharmacology · 2023Article
- LTT and HLA testing as diagnostic tools in Spanish vancomycin-induced DRESS cases: A case-control study.Frontiers in pharmacology · 2022Article
- Chronic kidney disease is potentially an independent prognostic factor for death in Stevens-Johnson syndrome and toxic epidermal necrolysis patients.Frontiers in medicine · 2022Article
- Current Perspectives on Severe Drug Eruption.Clinical reviews in allergy & immunology · 2021Review
- A Comprehensive Review ofPharmaceuticals (Basel, Switzerland) · 2021Review
- Association between serum ferritin and the severity of drug eruptions.Journal of clinical laboratory analysis · 2020Article
- An Updated Review of the Diagnostic Methods in Delayed Drug Hypersensitivity.Frontiers in pharmacology · 2020Review
- Genetic Diversity ofFrontiers in pharmacology · 2020Article
- Applications of Immunopharmacogenomics: Predicting, Preventing, and Understanding Immune-Mediated Adverse Drug Reactions.Annual review of pharmacology and toxicology · 2019Review
- Epidemiology of Severe Cutaneous Adverse Drug Reaction and Its HLA Association among Pediatrics.Iranian journal of pharmaceutical research : IJPR · 2019Article
- Treatment of severe drug reactions by hemodialysis.International journal of dermatology · 2018Article
- Segmental Erythema Multiforme-Like Drug Eruption by Aromatase Inhibitor Anastrozole - First Case Report and another Example of an Immunocompromised District.Open access Macedonian journal of medical sciences · 2018Article
- The Epidemiology of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis in China.Journal of immunology research · 2018Article
- Association between HLA-B Alleles and Carbamazepine-Induced Maculopapular Exanthema and Severe Cutaneous Reactions in Thai Patients.Journal of immunology research · 2018Article
- An Updated Review of the Molecular Mechanisms in Drug Hypersensitivity.Journal of immunology research · 2018Review
- Allergy to chlorpromazine and valproic acid following carbamazepine hypersensitivity in a patient with an HLA-B*4601 allele.Neuropsychiatric disease and treatment · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Severe cutaneous adverse reactions (SCARs), previously thought to be idiosyncratic or unpredictable, are a deadly form of adverse drug reactions with skin manifestations. Current pharmacogenomic studies of SCARs have made important strides, as the prevention of SCARs, to some extent, appears attainable with the identification of genetic variants for genes encoding drug-metabolizing enzymes and human leukocyte antigens (HLAs). Despite the improvement of incidence, a treatment guideline for this devastating condition is still unavailable, highlighting the inadequacy of contemporary accepted therapeutic interventions. As such, prompt withdrawal of causative drugs is believed to be a priority of patient management. In this review, we discuss recent cutting-edge findings concerning the discovery of biomarkers for SCARs and their clinical utilities in the better prediction and early diagnosis of this disease. The knowledge compiled herein provides clues for future investigations on deciphering additional genetic markers for SCARs and the design of clinical trials for the prospective identification of subjects at genetic risk for this condition, ultimately personalizing the medicine.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.